Management of Atrial Fibrillation

Initial Assessment and Anticoagulation

The European Society of Cardiology recommends initiating rate control with beta-blockers or non-dihydropyridine calcium channel blockers combined with anticoagulation based on stroke risk for most patients with atrial fibrillation, as this approach is equally effective as rhythm control for reducing mortality and cardiovascular events while causing fewer adverse effects 1
Upon diagnosis of atrial fibrillation, immediately assess hemodynamic stability, left ventricular function, and stroke risk, as these factors dictate the management approach 1, 2, 3
Calculate the CHA₂DS₂-VASc score to determine stroke risk, with a score of ≥2 in men or ≥3 in women indicating the need for oral anticoagulation 3, 4

The American College of Cardiology recommends beta-blockers, diltiazem, or verapamil as first-line options for rate control in patients with preserved ejection fraction (LVEF >40%) 1, 3, 5
For patients with reduced ejection fraction (LVEF ≤40%), use beta-blockers and/or digoxin, as calcium channel blockers are contraindicated due to negative inotropic effects 1, 2, 3

The European Heart Society recommends starting oral anticoagulation for all patients with a CHA₂DS₂-VASc score ≥2 in men or ≥3 in women, with direct oral anticoagulants (DOACs) preferred over warfarin due to lower intracranial hemorrhage risk 1, 3
Continue anticoagulation indefinitely based on stroke risk, regardless of whether sinus rhythm is restored, as most strokes occur after anticoagulation is stopped or when subtherapeutic 1, 3

For patients with heart failure and recent hospitalization, consider AV node ablation combined with cardiac resynchronization therapy for severely symptomatic patients with permanent AF and ≥1 heart failure hospitalization 1, 3
In patients with COPD or active bronchospasm, use diltiazem or verapamil as first-line, avoiding beta-blockers during active bronchospasm 1, 2, 3

Consider rhythm control strategy for symptomatic patients despite adequate rate control, young patients with new-onset AF, suspected tachycardia-induced cardiomyopathy, or hemodynamically unstable patients 1, 3, 6
For AF duration >48 hours or unknown duration, provide 3 weeks of therapeutic anticoagulation before cardioversion, and continue anticoagulation for a minimum of 4 weeks after cardioversion 1, 3, 4

Reassess therapy periodically and evaluate for new modifiable risk factors, monitoring renal function at least annually when using DOACs, and continuing anticoagulation according to stroke risk regardless of rhythm status 1, 2, 3, 4